Therapeutic drug monitoring (TDM) has emerged as a useful tool for optimising the use of
biologics, and in particular anti-tumour necrosis factor (anti-TNF) therapy, in inflammatory …

Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN
guideline on the medical management of paediatric Crohn's disease [CD]. Methods We …

The implementation of therapeutic drug monitoring (TDM) in the inflammatory bowel disease
practice has evolved over the years. In the early days, the focus was merely on measuring …

Abstract Background and Aims Accelerated infliximab (IFX) induction is often based on
clinical parameters as opposed to pharmacokinetics (PK). We aimed to investigate the …

Infliximab (IFX) is administered intravenously using weight-based dosing (5 mg/kg) in
inflammatory bowel disease (IBD) patients. Our hypothesis is that especially young children …

Biologic therapies have revolutionized the management of inflammatory bowel disease
[IBD], but primary and secondary non-responses occur in a significant proportion of patients …

Standard‐of‐care infliximab dosing regimens were developed prior to the routine use of
therapeutic drug monitoring and identification of target concentrations. Not surprisingly …

Abstract Purpose of the Review This review focuses on recent advancements in anti-TNF
therapeutic drug monitoring (TDM), pharmacogenetics and personalized drug selection for …

Abstract Background and Aims Adequate infliximab concentrations during induction
treatment are predictive for deep remission [corticosteroid-free clinical and endoscopic …

The pharmacotherapy of inflammatory bowel diseases (Crohn's disease and ulcerative
colitis) has experienced significant progress with the advent of monoclonal antibodies …